Analyst Activity – Cowen and Company Reiterates Market Perform on Keryx Biopharmaceuticals (NASDAQ:KERX)

ME Staff
-
0

Analyst Ratings For Keryx Biopharmaceuticals (NASDAQ:KERX)

Today, Cowen and Company reiterated its Market Perform rating on Keryx Biopharmaceuticals (NASDAQ:KERX).

There are 5 hold ratings, 4 buy ratings on the stock.

The current consensus rating on Keryx Biopharmaceuticals (NASDAQ:KERX) is Hold (Score: 2.44) with a consensus target price of $8.60 per share, a potential 17.97% upside.

Some recent analyst ratings include

  • 7/25/2017-Cowen and Company Reiterated Rating of Market Perform.
  • 7/20/2017-Maxim Group Reiterated Rating of Buy.
  • 1/11/2017-Citigroup Inc. Upgrade from a “Sell ” rating to a ” Neutral” rating.
  • 11/19/2016-FBR & Co Reiterated Rating of Hold.
  • 9/8/2016-JMP Securities Reiterated Rating of Outperform.

Recent Insider Trading Activity For Keryx Biopharmaceuticals (NASDAQ:KERX)
Keryx Biopharmaceuticals (NASDAQ:KERX) has insider ownership of 3.08% and institutional ownership of 62.26%.

  • On 7/5/2017 Brian Adams, General Counsel, sold 641 with an average share price of $7.67 per share and the total transaction amounting to $4,916.47. View SEC Filing
  • On 7/5/2017 Greg Madison, Insider, sold 910 with an average share price of $7.67 per share and the total transaction amounting to $6,979.70. View SEC Filing
  • On 4/28/2017 Scott A. Holmes, CFO, sold 1,219 with an average share price of $5.89 per share and the total transaction amounting to $7,179.91. View SEC Filing
  • On 4/24/2017 John F. Neylan, Insider, sold 1,209 with an average share price of $5.73 per share and the total transaction amounting to $6,927.57. View SEC Filing
  • On 4/17/2017 Brian Adams, General Counsel, sold 1,090 with an average share price of $5.75 per share and the total transaction amounting to $6,267.50. View SEC Filing
  • On 4/5/2017 Brian Adams, General Counsel, sold 642 with an average share price of $5.80 per share and the total transaction amounting to $3,723.60. View SEC Filing
  • On 4/5/2017 Greg Madison, Insider, sold 911 with an average share price of $5.80 per share and the total transaction amounting to $5,283.80. View SEC Filing

Recent Trading Activity for Keryx Biopharmaceuticals (NASDAQ:KERX)
Shares of Keryx Biopharmaceuticals closed the previous trading session at 7.43 up +0.14 1.92% with 1,270,814 shares trading hands.